Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
07 Jun 2023
Gene Therapy
CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the following investor conferences in June 2023. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Jefferies Global Healthcare Conference
Presentation: Friday, June 9, 2023, at 10:00 a.m. ET at the Marriott Marquis, New York City
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings on Friday, June 9
Goldman Sachs 44th Annual Global Healthcare Conference
Fireside chat: Thursday, June 15, 2023, at 10:00 a.m. PT at the at Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA.
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings on Wednesday, June 14, and Thursday June 15
A webcast of the presentation and fireside chat can also be accessed under “Events & Presentations” in the Investors section of Foghorn’s website, , and will be available for 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics Inc. is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. Foghorn is developing multiple product candidates in oncology. For more information about Foghorn, visit our website at , and follow us on Twitter and LinkedIn.
Contact:
Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
bstrain@foghorntx.com
Karin Hellsvik, Foghorn Therapeutics Inc. (Media)
khellsvik@foghorntx.com
Michael Lampe, ScientPR (Media)
michael@scientpr.com
Hans Vitzthum, LifeSci Advisors (Investors)
hans@lifesciadvisors.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.